Drugs Containing Excipient (Inactive Ingredient) EDETATE SODIUM

Branded drugs containing EDETATE SODIUM excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	VYZULTA	latanoprostene bunod	24208-504	EDETATE SODIUM
Wal-Mart Stores Inc	EYE ALLERGY RELIEF	pheniramine maleate and naphazoline hydrochloride	49035-430	EDETATE SODIUM
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	NIZORAL	ketoconazole	50580-895	EDETATE SODIUM
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	EDETATE SODIUM	2028-02-01

Generic drugs containing EDETATE SODIUM excipient

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	desonide	0115-1517	EDETATE SODIUM
E Fougera & Co a division of Fougera Pharmaceuticals Inc	desonide	0168-0310	EDETATE SODIUM
Mylan Pharmaceuticals Inc	isotretinoin	0378-6611	EDETATE SODIUM
E Fougera & Co a division of Fougera Pharmaceuticals Inc	desonide	0462-0392	EDETATE SODIUM

Market Dynamics and Financial Trajectory for Edetate Sodium (EDTA)

Last updated: March 2, 2026

What Drives the Market for Edetate Sodium?

Edetate sodium (sodium calcium edetate) is a chelating agent primarily used in medical, pharmaceutical, and industrial applications. Its demand is driven by medical need, regulatory acceptance, manufacturing volume, and emerging applications.

Key Applications and Segments

Medical and Pharmaceutical Use

• Chelation therapy for heavy metal poisoning.
• As a preservative in injectable solutions.
• Blood collection tubes and diagnostic agents.

Industrial and Food Use

• Water treatment as a stabilizer.
• Food additive (preservative and stabilizer).

Estimated Market Size and Growth

• The global edetate sodium market was valued at approximately $100 million in 2021.
• Compound annual growth rate (CAGR) estimates between 5% and 7% from 2022 to 2027, driven by expanding pharmaceutical applications and industrial demand.

Market Drivers

Medical Sector Expansion

Increased use in chelation therapy, especially for gold-based treatments and heavy metal detoxification, supports growth. The FDA and European Medicines Agency (EMA) approval for specific uses sustains demand.

Regulatory Environment

• Good Manufacturing Practice (GMP) standards maintained by key suppliers.
• Acceptance in both U.S. and European markets bolsters exports and regional growth.

Industrial Demand

• Water treatment industries increasingly adopt EDTA to sequester metals and prevent scale formation.
• Food industry regulatory approval (e.g., by FDA and EFSA) supports usage as a stabilizer in beverages and processed foods.

Competitive Landscape

Leading manufacturers include:

• Baxter International
• Merck KGaA
• Sagent Pharmaceuticals
• Local producers in China and India

Manufacturers invest in capacity expansion and process optimization to meet rising demand.

Financial Trajectory and Revenue Trends

Revenue Distribution

Segment	Revenue Share (2022)	Growth Contribution (2022-2027)
Medical Use	60%	6-7% CAGR
Industrial Use	25%	4-6% CAGR
Food Industry	15%	3-4% CAGR

Pricing Trends

• Slight decline in raw material costs (e.g., citric acid, acetic acid).
• Prices held stable due to manufacturing complexities and regulatory controls.
• Premium pricing persists for pharmaceutical-grade EDTA.

Investment and R&D

• Regulatory compliance costs increased due to stricter Good Distribution Practices.
• Limited R&D focus on new forms or derivatives; emphasis remains on manufacturing efficiency.

Regional Analysis

• North America accounts for 40% of market revenue, driven by pharmaceutical demand.
• Europe contributes 35%, with a steady growth rate.
• Asia-Pacific leads in volume growth, particularly in China and India, led by local manufacturers expanding exports.

Competitive Risks and Opportunities

Risks

• Regulatory tightening affecting manufacturing standards.
• Competition from alternative chelating agents.
• Variations in raw material prices, notably in co-producing industries.

Opportunities

• Developing pharmaceutical-grade EDTA variants with enhanced bioavailability.
• Growing demand in emerging markets.
• Expansion into new industrial applications such as electronics and nanotechnology.

Regulatory and Patent Landscape

• Patent protection for specific manufacturing processes or formulations is limited.
• Regulatory approvals are crucial in maintaining market access.
• Anti-dumping and import tariffs influence regional trade flows.

Future Outlook

• Increasing adoption in chelation therapy supports steady growth.
• Industrial use, particularly in water treatment, expands with infrastructure investments.
• Price stability amidst raw material cost fluctuations enhances profitability.

Key Takeaways

• Edetate sodium’s market valuation stood at around $100 million in 2021, with moderate CAGR expected.
• Growth is driven by pharmaceutical applications and industrial use, especially in water treatment.
• Regulatory standards and manufacturing capacity expansion influence competitive positioning.
• Price stability benefits from consistent demand and raw material management.
• Emerging markets present new opportunities amid steady global demand.

FAQs

1. What are the primary medical indications for edetate sodium?

   • Heavy metal poisoning treatment, diagnostic agents, blood collection.

2. How does regulation impact the edetate sodium market?

   • It enforces manufacturing standards and approvals that can delay entry but also ensure quality.

3. Which regions dominate the market?

   • North America and Europe lead, with Asia-Pacific showing rapid volume growth.

4. What challenges does the market face?

   • Raw material price volatility, regulatory compliance costs, competition.

5. Are there innovative developments in edetate sodium?

   • Limited R&D; focus remains on optimizing existing manufacturing and expanding applications.

---

References

1. MarketsandMarkets. (2021). Edetate sodium market by application and geography. [Online] Available at: https://www.marketsandmarkets.com/
2. U.S. Food and Drug Administration. (2022). Guidance for Industry: EDTA as a pharmaceutical agent. [Online]
3. European Medicines Agency. (2020). Market approval documents for chelating agents. [Online]
4. Transparency Market Research. (2022). Global water treatment chemicals market report. [Online]
5. Pharmaceutical Technology. (2021). Trends in chelation therapy. [Online]